Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-85

So is this it in a nut shell:

- we have bought a CAR-T for $12m
- That CAR-T has been greenlighted to go straight to a registrational trial
- Because of its orphan status that trial is way quicker and easier
- The trial will cost $20m

If I am correct in my understanding then those are all the good things about this deal. Indeed, it seems a good deal period. The bad aspect is the CAP Raise. Totally unnecessary and certainly should not have been done at a discount. Could have been funded from existing cash.

I don't agree that we should have bought this company given they hold other tech we don't need and the license price was about as cheap as it gets. I would hope there is still more announcements to come before we trade again. I hope they just consolidate now and dual list on the nasdaq to get it over with. I think that would help lift the SP.